Publicaciones científicas
Efficacy of Omalizumab for the treatment of Bullous Pemphigoid. Spanish multicenter real-world experience
Álvaro Aguado Vázquez 1 , Andrea Estébanez Corrales 1 , F Javier Melgosa-Ramos 1 , José Manuel Mascaró Galy 2 , Jon Fulgencio-Barbarin 3 , Xavier Bosch Amate 2 , Laia Curto Barredo 4 , Mar Blanes-Martínez 5 , Ricardo Ruiz Villaverde 6 , Asunción Ballester Martínez 7 , Daniel Martín-Torregrosa 8 , Juan Luis Castaño Fernández 9 , Rita Cabeza Martínez 9 , Amparo Pérez-Ferriols 10 , Daniel Ramos Rodríguez 11 , Julian Boix Vilanova 12 , Gemma Melé-Ninot 13 , Vicente Expósito Serrano 14 , Agustin España Alonso 15 , Almudena Mateu-Puchades 1
Background: Bullous Pemphigoid (BP) is the most common autoimmune blistering disease. Most patients are elderly and associate multiple comorbidities. Topical and systemic corticosteroids are considered as the first-line treatment for BP and immunosuppressors are used as steroid-sparing treatments but both have side effects and contraindications which are even more common in this elderly population. New treatments targeting interleukins and receptors related to BP pathogenesis have been proposed to decrease this side effects while achieving equal or better effectiveness response rates.Omalizumab is a monoclonal antibody that targets IgE that has been proposed for the treatment of BP due to the evidence that IgE autoantibodies play an essential role in BP pathogenesis.
Objectives and methodology: To assess the efficacy and security of Omalizumab for the treatment of BP, we carried out a multicenter, retrospective, observational study including patients diagnosed of BP who received omalizumab for at least 3 months from 15 tertiary hospitals in Spain. IgE levels prior to treatment was measured and we evaluate the possible correlation with clinical response. We excluded patients treated with Omalizumab for less than 3 months as we consider this duration is insufficient for a comprehensive assessment of its efficacy. To evaluate the effectiveness of the treatment we used the percentage of BSA improvement.
Results: We included 36 patients. The vast majority associate multiple comorbidities and all patients had used other systemic therapies apart from corticoids before Omalizumab.83% experienced some kind of treatment response and 42% of all patient treated achieved complete response.We did not find any correlation between higher levels and a better response (p=0,1791).All patients tolerated Omalizumab without reported side-effects.
Conclusions: Omalizumab is a good therapeutic alternative for BP as it obtained clinical response in most patients and nearly half of the cases achieving complete response. It showed no side effects which is crucial in elderly patients suffering from BP.
CITA DEL ARTÍCULO Clin Exp Dermatol. 2024 Mar 2:llae067. doi: 10.1093/ced/llae067
Nuestros autores
